German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
Authors: doc. MUDr. Přemysl Falt, Ph.D.
Authors: Prim. MUDr. Spyridon Gkalpakiotis, MBA. Ph.D.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
